Blenrep works better than Darzalex as early therapy, trial data show
When added to a second-line combination therapy, Blenrep (belantamab…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA delays its decision on earlier Abecma treatment for RRMM
The U.S. Food and Drug Administration (FDA) is delaying…
1st patient dosed in Phase 1 trial of triple-target treatment ISB 2001
The first multiple myeloma patient has been dosed…
Foundation awards $21M in grants for multicenter myeloma research
Three research projects have been awarded $7 million each…
Xpovio combo plus mezigdomide to be tested in relapsed-refractory MM
A Phase 1/2 clinical trial will evaluate the safety…
Survival rates by race found similar with Abecma in myeloma study
Safety and response rates with Abecma (idecabtagene vicleucel) were…
